The History Behind Our Products

The peptide-nucleic acid composition, Reticulose, was allowed to be sold in this country until 1960, and in that year alone, over 1,000 physicians used over 1.2 million ampuls in the United States with an unparalleled perfect safety record. Then through a series of quirk circumstances, the FDA had it de-certified, not allowing it to be sold in the US.

Reticulose was then manufactured overseas, and due to financial difficulties sank into relative obscurity until the mid 1980's when it resurfaced as the AIDS epidemic took hold, and people wondered whether it could be useful in the care of this dreaded scourge.

The product proved its worth in 1992 when 100% of a small trial group had successful results. In 1996 a change was made to the method of manufacturing by Dr. Bonawentura Kochel, and an improved peptide nucleic-acid composition, Immax, was created, and a US patent for it was granted in December of 1998.

This composition underwent clinical testing in Cambodia in 1997 for AIDS, Hepatitis C, and Genital Herpes, and it proved efficacious in all areas. In 1998, in Gabon, Africa, 10 children were successfully cared for who had Malaria, and the Government of Gabon recognized the success and registered it in that country.

Similar results during the period 1999-2000, when over 40 people reported successful results when care for with various types of cancers, as well as for Hepatitis C, in an experimental research project in the Dominican Republic.

During early 2006, as a result of the enormous increase in available technology and much improved methods of laboratory testing, once again with a significant breakthrough, Dr. Bonawentura Kochel, Professor, Wroclaw University of Medicine, and head researcher for Immune@Work™ Inc., discovered an advanced protein peptide composition without nucleic acid, and also improved the manufacturing process, such that various portions/fractions of the composition can be isolated and tailored to more effectively assist the immune system in fighting various diseases and illnesses.

Dr. Kochel's recent enhancements also allow Immune@Work Plus™ to kill the malaria parasite within the blood cell in a matter of days. These currently pending patents are the basis for all current Immune@Work™ Inc. advanced protein peptide compositions that will produce safe and powerful products to enhance the desired human immune system.

The ingredients for Immune@Work™ Inc. advanced protein peptide compositions are from food derivatives and totally non-toxic. Some of the main ingredients are bovine albumin, casein from milk, laboratory tested meat cell culture, and pancreatin.

To learn more about our senior management, click here - or if you wish, please contact us at 734.447.5477 or info@immuneatwork.com.